URL has been copied successfully!
Skip to content
JBizNews
JBizNews
Primary Navigation Menu
Menu
  • Home
  • Breaking News
  • Top News
  • Markets
  • Crypto
  • Health
  • Real Estate
  • Subscribe
  • About

Health

  • April 2, 2026

    CDC stops testing for rabies, pox viruses


  • April 2, 2026

    STAT+: Beyond detection: In the age of clinical AI, what counts as an FDA ‘breakthrough’ medical device?


  • April 2, 2026

    STAT+: ‘Takeover Tuesday’ saves biotech’s quarter


  • April 2, 2026

    STAT reporter goes up against radiologists to spot deepfake X-rays


  • April 2, 2026

    Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?


  • April 2, 2026

    Opinion: Medical misinformation wins when patients can’t see their doctors


  • April 1, 2026

    STAT+: Trump administration prepares 100% tariffs on some imported drugs


  • April 1, 2026

    STAT+: Makary marks one year at FDA with focus on achievements in speech to staff


  • April 1, 2026

    STAT+: Government watchdog urges FDA to finalize guidance for advisory committee conflicts of interest


  • April 1, 2026

    STAT+: Large AI scribe study finds modest time savings, inconsistent use


  • April 1, 2026

    Elevance sidesteps Medicare Advantage sanctions for now


  • April 1, 2026

    Over 130 hospitals sue HHS over DSH payments


  • April 1, 2026

    Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk


  • April 1, 2026

    Bipartisan lawmakers urge CMS to crack down on Medicare Advantage overpayments


  • April 1, 2026

    STAT+: Novo’s subscription model raises questions about pharma-telehealth tie-ups


  • April 1, 2026

    STAT+: Insilico Medicine CEO on how best to use AI in drug development


  • April 1, 2026

    STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more


  • April 1, 2026

    CMS tackles big policy changes with diminished workforce


  • April 1, 2026

    One year after HHS layoffs, a department in disarray


  • April 1, 2026

    STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?


  • April 1, 2026

    STAT+: NIH director’s invocation of Vannevar Bush’s legacy to promote Trump science policies sparks pushback


  • April 1, 2026

    STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch


  • April 1, 2026

    Why an ovary syndrome may get a new name: Men seem to have PCOS, too


  • April 1, 2026

    Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression


  • April 1, 2026

    Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene


  • March 31, 2026

    STAT+: The HSA industry makes its MAHA pitch


  • March 31, 2026

    HHS reverses Biden-era tech reorganization, returns ONC name


  • March 31, 2026

    STAT+: HHS changes the U.S. health IT office’s name, and its purview


  • March 31, 2026

    Elevance fills slew of mid-level leadership positions


  • March 31, 2026

    STAT+: Baby KJ scientists hit speed bump in quest to scale custom gene editor


  • March 31, 2026

    STAT+: OpenEvidence inks deal with major health system


  • March 31, 2026

    Supreme Court rules against Colorado ban on ‘conversion therapy’ for LGBTQ kids


  • March 31, 2026

    Lilly’s AI commitment expands through deal with Insilico


  • March 31, 2026

    STAT+: Pharmalittle: We’re reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more


  • March 31, 2026

    A new survey examines mental health outcomes of gender euphoria


  • March 31, 2026

    STAT+: Psychedelic biotechs face scrutiny over YouTube promos


  • March 31, 2026

    STAT+: Whoop, maker of health and fitness tracking wristbands, valued at $10 billion after latest fundraising


  • March 31, 2026

    STAT+: Biogen to acquire immunology biotech Apellis for $5.6 billion


  • March 31, 2026

    STAT+: Eli Lilly to buy Centessa Pharmaceuticals, maker of a narcolepsy drug, in $6.3B deal


  • March 31, 2026

    Opinion: America needs more clinics of last resort for patients who can’t get answers


Previous Page
1 … 4 5 6 7
Next Page
2026-03-30

JBIZNEWS LLC © 2026